Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Cost of vaccines becoming unaffordable in developing countries, charity warns

The cost of vaccines recommended by the World Health Organization has gone up 68-fold over the past 13 years, according to international aid charity Médecins sans Frontières.


The cost of vaccines recommended by the World Health Organization (WHO) for developing countries has increased by 68%, warns Médecins sans Frontières (MSF)

Source: thomas koch /

Governments are facing tough choices about which diseases they can afford to protect their children against, says Médecins sans Frontières

The number of diseases a child can be immunised against has doubled in the past 13 years, but the cost of vaccines recommended by the World Health Organization (WHO) has gone up 68-fold, warns the international aid charity Médecins sans Frontières (MSF).

In 2001, WHO’s childhood immunisation schedule included vaccinations against six diseases which cost US$0.67. By 2014, the number of diseases included in the WHO programme had increased to 12 but the total cost of the vaccines had risen to between US$32.09 and US$45.59 — a 68-fold increase, the MSF calculates.

The actual costs may be even higher as the figures used by MSF were based on the lowest available price of vaccines for a selected number of developing countries that are eligible for a financial subsidy from the Global Alliance for Vaccines and Immunisation (Gavi), a public-private partnership, to offset the cost of the products.

In countries where governments individually negotiate with drug manufacturers, the prices can be more than 20 times higher than in those that qualify for a Gavi or UNICEF financial subsidy, it says.

The MSF report, ‘The right shot: Bringing down barriers to affordable and adapted vaccines’, highlights that the price of the pneumococcal vaccine accounted for 45% of the total vaccination bill for a child who completed the recommended WHO programme. The charity is calling on GlaxoSmithKline and Pfizer to cut the price of their pneumococcal vaccines to US$5 per child for all three doses.

The call comes a year before more than 25% of developing countries are due to lose their Gavi subsidy, which means they will face price increases that many governments will not be able to afford, MSF says.

“We have an irrational situation where some developing countries like Morocco and Tunisia are paying more for the pneumococcal vaccine than France does,” says Kate Elder, vaccines policy officer for MSF’s access campaign.

“Because of the astronomical cost of new vaccines, many governments are facing tough choices about which deadly diseases they can afford to protect their children against.”

Elder says governments need to put pressure on drug manufacturers to offer better prices to Gavi-assisted countries: “Life-saving vaccines for children should not be big business in poor countries.”

The MSF report has been published ahead of Gavi’s pledging conference in Berlin on 27 January 2015, which aims to mobilise funds for global immunisation programmes.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067637

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.